When Lobbying Turns: Lessons From The Gun Control Debate For Pharma
Executive Summary
The sudden shift in the politics of gun control is the latest example of how a long record of lobbying success can turn quickly.
You may also be interested in...
The Budget Blindside: Did Pharma Fight The Wrong Battle?
The bigger 'Donut Hole' discount is a rare loss for pharma on Capitol Hill – one that may in part be because industry did too good a job fighting off a different drug pricing measure.
As US House Changes Hands, CMS May Face More Oversight Than FDA
Key Republican committee chairs on health issues are familiar faces, largely supportive of the US FDA’s approach to drug regulation. Implementation of the new pricing law, however, will get a lot more scrutiny.
Status Quo Senate Still Means Big Changes For FDA Oversight
The mid-term elections left the US Senate under Democratic leadership – but there are still big changes coming that may make life tougher on FDA and the brand name industry.